Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C29H33ClN2O3 |
| Molecular Weight | 493.037 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)C(CC[N@+]1([O-])CC[C@](O)(CC1)C2=CC=C(Cl)C=C2)(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=KXVSBTJVTUVNPM-UKPNQBOSSA-N
InChI=1S/C29H33ClN2O3/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32(35)20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3/t28-,32-
| Molecular Formula | C29H33ClN2O3 |
| Molecular Weight | 493.037 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Loperamide Oxide is a prodrug of loperamide, an antidiarrheal agent, patented by Belgian pharmaceutical company Janssen Pharmaceutica N. V. as an antidiarrheal agent. Loperamide oxide is reduced to loperamide and has the same antisecretory potency as loperamide in jejunum and colon. In clinical trials, Loperamide oxide provides a safe and effective treatment for chronic diarrhea associated with Crohn's disease. Loperamide Oxide is used in the Netherlands for the treatment of acute diarrhea in adults under brand name Arestal.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0055114 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7628301 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Loperamide oxide in the treatment of acute diarrhea in adults. | 1994-11-01 |
|
| Influence of loperamide and loperamide oxide on the anal sphincter. A manometric study. | 1992-09 |
|
| Effects of the prodrug loperamide oxide, loperamide, and placebo on jejunal motor activity. | 1992-02 |
|
| Dose proportionality study of loperamide following oral administration of loperamide oxide. | 1992 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8529776
1 or 2 mg after passage of each unformed stool for 1-week
The mean daily dose of loperamide oxide was 2.7 mg.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:22:38 GMT 2025
by
admin
on
Mon Mar 31 19:22:38 GMT 2025
|
| Record UNII |
NG66S4H2RL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
A07DA05
Created by
admin on Mon Mar 31 19:22:38 GMT 2025 , Edited by admin on Mon Mar 31 19:22:38 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
NG66S4H2RL
Created by
admin on Mon Mar 31 19:22:38 GMT 2025 , Edited by admin on Mon Mar 31 19:22:38 GMT 2025
|
PRIMARY | |||
|
100000082027
Created by
admin on Mon Mar 31 19:22:38 GMT 2025 , Edited by admin on Mon Mar 31 19:22:38 GMT 2025
|
PRIMARY | |||
|
DTXSID80883171
Created by
admin on Mon Mar 31 19:22:38 GMT 2025 , Edited by admin on Mon Mar 31 19:22:38 GMT 2025
|
PRIMARY | |||
|
SUB27172
Created by
admin on Mon Mar 31 19:22:38 GMT 2025 , Edited by admin on Mon Mar 31 19:22:38 GMT 2025
|
PRIMARY | |||
|
6139
Created by
admin on Mon Mar 31 19:22:38 GMT 2025 , Edited by admin on Mon Mar 31 19:22:38 GMT 2025
|
PRIMARY | |||
|
SUB08573MIG
Created by
admin on Mon Mar 31 19:22:38 GMT 2025 , Edited by admin on Mon Mar 31 19:22:38 GMT 2025
|
PRIMARY | |||
|
C174757
Created by
admin on Mon Mar 31 19:22:38 GMT 2025 , Edited by admin on Mon Mar 31 19:22:38 GMT 2025
|
PRIMARY | |||
|
1370065
Created by
admin on Mon Mar 31 19:22:38 GMT 2025 , Edited by admin on Mon Mar 31 19:22:38 GMT 2025
|
PRIMARY | |||
|
106900-12-3
Created by
admin on Mon Mar 31 19:22:38 GMT 2025 , Edited by admin on Mon Mar 31 19:22:38 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |